Riley Hospital for Children | TRIALNET Type 1 Diabetes TrialNet

Indiana University

705 Riley Hospital Dr

Indianapolis, IN 46202

United States

Riley Hospital for Children is one of twenty-five Type 1 Diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Principal Investigator, Linda DiMeglio, MD, the TrialNet team at the Riley's is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Our Team

Principal Investigators

Linda

DiMeglio

MD, MPH

After graduating from Harvard University with honors, Dr. DiMeglio obtained her MD from the University of Pennsylvania in Philadelphia, PA and performed her residency in Pediatrics at Children’s Memorial Hospital (Northwestern University) in Chicago, IL. She completed her fellowship in Pediatric Endocrinology and received her Master’s in Public Health from Indiana University-Purdue University, Indianapolis. Since her fellowship, Dr. DiMeglio has been working in clinical research with a focus on Type 1 diabetes prevention and treatments, including new technologies and therapies for metabolic bone disease. She currently directs Riley Hospital’s participation in a number of type 1 diabetes research networks and supervises a research staff of 5 nurses and three technicians. She also collaborates on a variety of other translational and clinical research projects. She is an active clinician, seeing patients with diabetes and endocrine disorders in clinics, and she teaches medical students, residents, housestaff, and fellows.

Emily

Sims

Research interests include different pathophysiologic processes affecting beta cell function in Type 1 and Type 2 Diabetes; clinical interests include pediatric endocrinology and diabetes. I am originally from the Southeast, but have enjoyed living in the Midwest with my husband and two sons, and becoming a part of the Riley community.

Carmella

Evans-Molina

The long-range goal of the Evans-Molina lab is to define the pathways that govern beta cell function in states of health in order to understand how these regulatory circuits are impaired in the pathologic state of Type 2 diabetes mellitus. The major focus of the lab is to characterize changes in expression and activity of the sarco-endoplasmic reticulum Ca2+ ATPase or SERCA pump in the diabetic beta cell and to identify the downstream effects of SERCA dysregulation on ER calcium homeostasis, insulin production and secretion, and beta cell survival.

Research Coordinators

Maria

Spall

RN, CCRP

LaShondra

DeYampert

Maureen

Mullen

Megan

Hildinger

Regional Affiliates

Ann Arbor

University of Michigan Health System
1500 E. Medical Center Dr, Ann Arbor, MI 48109

Chicago

Ann & Robert H. Lurie Childrens Hospital of Chicago
225 E Chicago, Chicago, IL 60611

Detroit

Childrens Hospital of Michigan
3901 Beaubien Blvd, Detroit, MI 48201

Detroit

Henry Ford Medical Center
3031 West Grand Blvd, Detroit, MI 48202

Detroit

St. Johns Hospital & Medical Center
22201 Moross Road, SCPB II, Suite 270, Detroit, MI 48236

Fort Wayne

Lutheran Childrens Hospital
7950 W. Jefferson Blvd, suite 210, Fort Wayne, IN 46804

Grand Rapids

DeVos Childrens Hospital at Spectrum Health Hospitals
15 Michigan Street NE, Suite 701, Grand Rapids, MI 49503

Joliet

Presence Saint Joseph Medical Center
333 N. Madison St., Joliet, IL 60435

Kalamazoo

Western Michigan University School of Medicine
1000 Oakland Drive, Kalamazoo, MI 49008

Lexington

University of Kentucky
1101 Veterans Drive 111-C, Lexington, KY 40502

Peoria

University of Illinois College of Medicine at Peoria
530 NE Glen Oak Ave, Peoria, IL 61637

Springfield

Springfield Clinic
1130 South 6th St. Ste. 100, Springfield, IL 62703

Toledo

The University of Toledo
2142 North Cove Blvd., Conrad Jobst Tower, Suite 980, Toledo, OH 43606

Research Studies

Risk Screening

Pathway to Prevention

If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.

Prevention Study

Abatacept

TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.

Teplizumab

We are testing the drug teplizumab to see if it can delay or prevent progression of early stage T1D (stage 2) and prevent clinical diagnosis (stage 3). In earlier studies in people newly diagnosed (stage 3), teplizumab helped to prolong insulin production.

Longterm

Long-Term Investigative Follow-Up in TrialNet (LIFT)

Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.